← Oncology Approval Tracker

FDA DECISION ·

Vyloy

zolbetuximab-clzb · Astellas Pharma

FDA approvalNew therapyGastric and gastroesophageal junction cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment with fluoropyrimidine and platinum chemotherapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is CLDN18.2 positive on an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The CLDN18.2 antibody opens a new biomarker-based option in first-line gastric and junctional cancer.

What research teams should watch

Plan HER2 and CLDN18.2 testing together and prepare antiemetic and infusion workflows for nausea and vomiting.

PRIMARY RECORDS

Sources